Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 309
- Registration Number
- NCT02546700
- Locations
- 🇺🇸
Centex Studies, Houston, Texas, United States
🇺🇸Comprehensive Clinical Research Inc., Berlin, New Jersey, United States
🇺🇸Clinical Research Inst. of Southern Oregon, Pc, Medford, Oregon, United States
An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)
- Conditions
- Kidney Disease, Chronic
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 393
- Registration Number
- NCT02547454
- Locations
- 🇸🇮
Hospital Celje; Dept For Kidney Disease & Dialysis, Celje, Slovenia
🇸🇮Splosna Bolnisnica Izola; Oddelek Za Nefrologijo, Izola, Slovenia
🇸🇮Clinical Centre Ljubljana; Clinical Dep. For Nephrology, Ljubljana, Slovenia
A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT02546869
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Biological: 23-PPVBiological: 13-PCV BoosterBiological: Influenza VaccineBiological: KLHDrug: OCRBiological: TT Vaccine
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 102
- Registration Number
- NCT02545868
- Locations
- 🇺🇸
The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States
🇺🇸Territory Neurology and Research Institute, Tucson, Arizona, United States
🇺🇸North Central Neurology Associates, Cullman, Alabama, United States
A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 447
- Registration Number
- NCT02545283
- Locations
- 🇫🇷
Hopital Claude Huriez; Hematologie, Lille, France
🇫🇷Institut J Paoli I Calmettes; Onco Hematologie 2, Marseille, France
🇫🇷Hopital Saint Louis; Oncologie Medicale, Paris, France
Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT02542436
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 87
- Registration Number
- NCT02541604
- Locations
- 🇨🇭
Universitäts-Kinderspital; Abteilung für Onkologie, Zürich, Switzerland
🇮🇹Azienda Ospedaliera di Padova; Clinica di Onco-ematologia pediatrica, Padova, Veneto, Italy
🇪🇸Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona, Spain
Observational Study of MIRCERA in Users of Self-Application and Multidose Systems
- Conditions
- Renal Anemia of Chronic Kidney Disease
- Interventions
- Device: MIRCERA
- First Posted Date
- 2015-09-03
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 240
- Registration Number
- NCT02540213
Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 483
- Registration Number
- NCT02537691
- Locations
- 🇱🇻
Riga 1st hospital, outpatient clinic Bruninieks, Riga, Latvia
🇱🇻Clinical Hospital Gailezers; Dept of Pulmonology, Riga, Latvia
🇱🇻Latvian University postgraduate institute, Riga, Latvia
An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant
- Conditions
- Anemia, Kidney Transplantation
- Interventions
- Drug: Methoxy-polyethyleneglycol epoetin beta
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 290
- Registration Number
- NCT02538107
- Locations
- 🇩🇪
Klinikum Hann. Münden, Nephrologisches Zentrum Niedersachsen, Hann. Münden, Germany